![William Philip Werschler, MD](http://s1.studyres.com/store/data/002180558_1-3f461ee1041c2f05fdfba129d1e9c88a-300x300.png)
William Philip Werschler, MD
... Two XXX/XXX Gels for treatment of Acne.” (2005) Graceway Pharmaceuticals “ Open Lable Safety and Pharmacokinetic Study of XXX for One , Two , or Three Treatment Cycles to Surface Areas Greater then 25 square centimeters with Actinic Keratosis. (2005-2007) Allergan “ A Double Blind Dose Comparison of ...
... Two XXX/XXX Gels for treatment of Acne.” (2005) Graceway Pharmaceuticals “ Open Lable Safety and Pharmacokinetic Study of XXX for One , Two , or Three Treatment Cycles to Surface Areas Greater then 25 square centimeters with Actinic Keratosis. (2005-2007) Allergan “ A Double Blind Dose Comparison of ...
hlee - OoCities
... – Was f/u duration adequate? – What is the magnitude of the risk? – Should I attempt to stop the exposure? ...
... – Was f/u duration adequate? – What is the magnitude of the risk? – Should I attempt to stop the exposure? ...
Pharmacologic treatment of chorea in Huntington disease
... not differ between groups. Patients receiving TBZ worsened on UHDRS Functional Checklist scores (⫹0.8 units vs ⫺0.4 units in placebo-treated patients, p ⫽ 0.02), which had small but significant correlations with worsening UHDRS parkinsonism (r ⫽ 0.24, p ⫽ 0.027) and HAM-D scores (r ⫽ 0.30, p ⫽ 0.006 ...
... not differ between groups. Patients receiving TBZ worsened on UHDRS Functional Checklist scores (⫹0.8 units vs ⫺0.4 units in placebo-treated patients, p ⫽ 0.02), which had small but significant correlations with worsening UHDRS parkinsonism (r ⫽ 0.24, p ⫽ 0.027) and HAM-D scores (r ⫽ 0.30, p ⫽ 0.006 ...
Dupilumab PIII EN
... that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forwardlooking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could caus ...
... that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forwardlooking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could caus ...
Sanofi and Regeneron Announce Positive Dupilumab Topline
... For the 16-week treatment period, the overall rate of adverse events (65-73 percent dupilumab and 65-72 percent placebo) was comparable between the dupilumab groups and the placebo groups. The proportion of patients who completed the treatment period was 88-94 percent for dupilumab and 80.5-82 perce ...
... For the 16-week treatment period, the overall rate of adverse events (65-73 percent dupilumab and 65-72 percent placebo) was comparable between the dupilumab groups and the placebo groups. The proportion of patients who completed the treatment period was 88-94 percent for dupilumab and 80.5-82 perce ...
Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial
... point estimates were determined using the method of Clopper and Pearson.19 Noninferiority for the primary and secondary efficacy outcomes was determined based on the lower limit of the 2-sided 95% confidence intervals for the difference in treatment response rates. The 95% confidence intervals were ...
... point estimates were determined using the method of Clopper and Pearson.19 Noninferiority for the primary and secondary efficacy outcomes was determined based on the lower limit of the 2-sided 95% confidence intervals for the difference in treatment response rates. The 95% confidence intervals were ...
... Participants who were only able to tolerate the 300mg/day dose will taper down for 4 days at 150mg/day. Participants who were only able to tolerate the 150mg/day do not need to taper down. 12.10 Data Safety Monitoring and Interim Analysis This section has been revised at the request of the UPPCRN Da ...
A randomized double blind comparison of
... for the same duration. In both the atosiban and placebo groups, women were medicated by intravenous bags which looked identical and were prepared by a dedicated nurse in the centre not involved in the study. Subjects, clinicians and laboratory staff were therefore blinded to the group assignment. Th ...
... for the same duration. In both the atosiban and placebo groups, women were medicated by intravenous bags which looked identical and were prepared by a dedicated nurse in the centre not involved in the study. Subjects, clinicians and laboratory staff were therefore blinded to the group assignment. Th ...
Review article: the current pharmacological therapies for hepatic
... disaccharides reduced blood ammonia levels and improved neuropsychiatric symptoms. However, rifaximin was associated with earlier, more marked improvements and was better tolerated than the nonabsorbable disaccharides. Rifaximin 1200 mg/day (n ¼ 50) was compared with lactitol 60 g/day (n ¼ 53) admin ...
... disaccharides reduced blood ammonia levels and improved neuropsychiatric symptoms. However, rifaximin was associated with earlier, more marked improvements and was better tolerated than the nonabsorbable disaccharides. Rifaximin 1200 mg/day (n ¼ 50) was compared with lactitol 60 g/day (n ¼ 53) admin ...
Amiodarone IV: Indications, Dosing, Clinical Studies
... bradycardia, and second- or third-degree AV block in the absence of a functioning pacemaker. • Cordarone I.V. should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of Cordarone therapy, ...
... bradycardia, and second- or third-degree AV block in the absence of a functioning pacemaker. • Cordarone I.V. should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of Cordarone therapy, ...
The Role of Prophylactic Antibiotics in COPD
... ii. No difference between metered dose inhalers or nebulizers c. Systemic corticosteroids i. Shorten recovery time, improve lung function, reduce risk of early relapse, treatment failure, and length of hospital stay ii. Dose of 30-40 mg prednisone per day for 7-14 days (limited evidence on duration) ...
... ii. No difference between metered dose inhalers or nebulizers c. Systemic corticosteroids i. Shorten recovery time, improve lung function, reduce risk of early relapse, treatment failure, and length of hospital stay ii. Dose of 30-40 mg prednisone per day for 7-14 days (limited evidence on duration) ...
Sinatra Anesthesiology
... commercially available and because, having been widely prescribed for many years in Europe, its analgesic efficacy and safety profile have been well characterized. The dose of 2 g propacetamol was chosen because it releases 1 g intravenous acetaminophen. During the screening visit scheduled within 2 ...
... commercially available and because, having been widely prescribed for many years in Europe, its analgesic efficacy and safety profile have been well characterized. The dose of 2 g propacetamol was chosen because it releases 1 g intravenous acetaminophen. During the screening visit scheduled within 2 ...
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
... investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core t ...
... investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core t ...
Analyses and Displays Associated with Demographics
... Consideration should also be given to applicable laws and regulations of countries when collecting and reporting demographic data. For example, when French subjects are a part of the study, it is not permitted to collect their race; hence the race of a French subject will always be blank unless spec ...
... Consideration should also be given to applicable laws and regulations of countries when collecting and reporting demographic data. For example, when French subjects are a part of the study, it is not permitted to collect their race; hence the race of a French subject will always be blank unless spec ...
Australian public assessment for Follitropin alfa (rch)
... whereas Gonal-f is presented in three pack sizes of 0.5, 0.75 and 1.5 mL, all at the same concentration as for Bemfola, 600 IU/mL but designed to deliver multiple doses of variable quantity as required. The PI and CMI for both products are remarkably uninformative about the mechanisms of these deliv ...
... whereas Gonal-f is presented in three pack sizes of 0.5, 0.75 and 1.5 mL, all at the same concentration as for Bemfola, 600 IU/mL but designed to deliver multiple doses of variable quantity as required. The PI and CMI for both products are remarkably uninformative about the mechanisms of these deliv ...
DE TESTIMONIO On the evidence for decisions about
... allocated randomly to groups of contemporaneously treated patients. Randomisation means that every patient in a study has a known (usually equal) chance of receiving each of the treatments. As a consequence, so-called selection bias* is minimised8–11 with both known (and unknown) confounding factors ...
... allocated randomly to groups of contemporaneously treated patients. Randomisation means that every patient in a study has a known (usually equal) chance of receiving each of the treatments. As a consequence, so-called selection bias* is minimised8–11 with both known (and unknown) confounding factors ...
Adalimumab for Severe Refractory Uveitis
... the eye, an option potentially associated with complications such as cataract, glaucoma and infection. In severe cases of uveitis, patients whose disease is not controlled on safe levels of prednisolone will require second line treatment with immunosuppressant drugs to prevent sight-loss. An 'antipr ...
... the eye, an option potentially associated with complications such as cataract, glaucoma and infection. In severe cases of uveitis, patients whose disease is not controlled on safe levels of prednisolone will require second line treatment with immunosuppressant drugs to prevent sight-loss. An 'antipr ...
Guide to Clinical Trials for People with Hepatitis C Second Edition
... postmarketing trials look at women and children, people with advanced liver disease, people from certain racial and ethnic groups, or people with other illnesses. Sometimes postmarketing trials look at different doses and durations of treatment to see if there is a better way to use a drug or a comb ...
... postmarketing trials look at women and children, people with advanced liver disease, people from certain racial and ethnic groups, or people with other illnesses. Sometimes postmarketing trials look at different doses and durations of treatment to see if there is a better way to use a drug or a comb ...
NBER WORKING PAPER SERIES ADAPTIVE MINIMAX-REGRET TREATMENT CHOICE, WITH APPLICATION
... convenience samples of volunteers rather than on random samples of the patient population of interest. Analyses of findings usually presume, often without justification, that the distribution of treatment response among the volunteers who participate in a trial is the same as in the relevant patient ...
... convenience samples of volunteers rather than on random samples of the patient population of interest. Analyses of findings usually presume, often without justification, that the distribution of treatment response among the volunteers who participate in a trial is the same as in the relevant patient ...
Early treatment with, and time receiving, first disease
... HAQ between those ever treated and those not treated (–0.01, 95% CI –0.20 to 0.19). In other words, after allowing for the fact that treatment is more likely to be given to those with severe and active IP, treatment has been shown to move patients onto a trajectory that they would have followed if t ...
... HAQ between those ever treated and those not treated (–0.01, 95% CI –0.20 to 0.19). In other words, after allowing for the fact that treatment is more likely to be given to those with severe and active IP, treatment has been shown to move patients onto a trajectory that they would have followed if t ...
pharmacist`s role in enhancing patient participation in clinical trial
... The possibility of unpleasant, serious or even life-threatening side effects to treatments, ineffective treatments, protocols requiring more time and attention than would a nonprotocol treatment, long distant travel to the study site, increased treatments, laboratory tests and x-rays, hospital stays ...
... The possibility of unpleasant, serious or even life-threatening side effects to treatments, ineffective treatments, protocols requiring more time and attention than would a nonprotocol treatment, long distant travel to the study site, increased treatments, laboratory tests and x-rays, hospital stays ...
- Lancaster EPrints
... they do represent different doses of the same drug, no assumptions are made concerning the dose-response relationship, and if they are different combinations of the same set of drugs, no interactions are ignored. A clinical trial is considered in which patients are randomised between k new treatment ...
... they do represent different doses of the same drug, no assumptions are made concerning the dose-response relationship, and if they are different combinations of the same set of drugs, no interactions are ignored. A clinical trial is considered in which patients are randomised between k new treatment ...
Hyaluronic Acid for Treatment of Osteoarthritis of
... placebo groups at different time periods and found a small improvement in rest pain at 2 and 6 weeks, although the clinical significance of the difference was questioned. [10] Studies comparing intra-articular HA to NSAIDS have led to conflicting results and have not clearly shown intra-articular HA ...
... placebo groups at different time periods and found a small improvement in rest pain at 2 and 6 weeks, although the clinical significance of the difference was questioned. [10] Studies comparing intra-articular HA to NSAIDS have led to conflicting results and have not clearly shown intra-articular HA ...
Bugs as Drugs, Part Two: Worms, Leeches, Scorpions, Snails, Ticks
... wrapped up to simulate the size and shape of a leech.14 Both leech therapy groups had significantly better pain scores on the WOMAC scale than the control group. Adverse effects of leech therapy were not observed in any of the three osteoarthritis studies. ...
... wrapped up to simulate the size and shape of a leech.14 Both leech therapy groups had significantly better pain scores on the WOMAC scale than the control group. Adverse effects of leech therapy were not observed in any of the three osteoarthritis studies. ...
PDF - Trials
... the sample size was smaller than 80 clinical cases in two studies [16,17], the biggest one being less than 130 clinical cases [18,19]. In addition, the side effects during acupuncture treatment and the follow-up tests were not reported in any of these trials. The design of the control group was illo ...
... the sample size was smaller than 80 clinical cases in two studies [16,17], the biggest one being less than 130 clinical cases [18,19]. In addition, the side effects during acupuncture treatment and the follow-up tests were not reported in any of these trials. The design of the control group was illo ...
Placebo-controlled study
![](https://commons.wikimedia.org/wiki/Special:FilePath/Cebocap.jpg?width=300)
Placebo-controlled studies are a way of testing a medical therapy in which, in addition to a group of subjects that receives the treatment to be evaluated, a separate control group receives a sham ""placebo"" treatment which is specifically designed to have no real effect. Placebos are most commonly used in blinded trials, where subjects do not know whether they are receiving real or placebo treatment. Often, there is also a further ""natural history"" group that does not receive any treatment at all.The purpose of the placebo group is to account for the placebo effect, that is, effects from treatment that do not depend on the treatment itself. Such factors include knowing one is receiving a treatment, attention from health care professionals, and the expectations of a treatment's effectiveness by those running the research study. Without a placebo group to compare against, it is not possible to know whether the treatment itself had any effect.Patients frequently show improvement even when given a sham or ""fake"" treatment. Such intentionally inert placebo treatments can take many forms, such as a pill containing only sugar, a surgery where nothing efficacious is actually done (just an incision and sometimes some minor touching or handling of the underlying structures), or a medical device (such as an ultrasound machine) that is not actually turned on. Also, due to the body's natural healing ability and statistical effects such as regression to the mean, many patients will get better even when given no treatment at all. Thus, the relevant question when assessing a treatment is not ""does the treatment work?"" but ""does the treatment work better than a placebo treatment, or no treatment at all?"" As one early clinical trial researcher wrote, ""the first object of a therapeutic trial is to discover whether the patients who receive the treatment under investigation are cured more rapidly, more completely or more frequently, than they would have been without it.""p.195 More broadly, the aim of a clinical trial is to determine what treatments, delivered in what circumstances, to which patients, in what conditions, are the most effective.Therefore, the use of placebos is a standard control component of most clinical trials, which attempt to make some sort of quantitative assessment of the efficacy of medicinal drugs or treatments. Such a test or clinical trial is called a placebo-controlled study, and its control is of the negative type. A study whose control is a previously tested treatment, rather than no treatment, is called a positive-control study, because its control is of the positive type.Government regulatory agencies approve new drugs only after tests establish not only that patients respond to them, but also that their effect is greater than that of a placebo (by way of affecting more patients, by affecting responders more strongly, or both). As a result, ""placebo-controlled studies often are designed in such a way that disadvantages the placebo condition"".